Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

P0DPI1 (BXA1_CLOBH) Clostridium botulinum (strain Hall / ATCC 3502 / NCTC 13319 / Type A)

Botulinum neurotoxin type A UniProtKBAFDB90v4InterProInteractive Modelling

1296 aa; Sequence (Fasta) ; 1 identical sequence: Clostridium botulinum: Q7B8V4

Available Structures

68 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
2.7 angstrom crystal structure of BoNT/Ai in complex with NTNHA Heteromer
Q45914;
1-1295
ZN;CA; 20×SO4;MES;
Assess
3.9 angstrom crystal structure of BoNT/Ai in complex with NTNHA Heteromer
Q45914;
1-1295
ZN;CA;
Assess
Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody CR1 Heteromer
2-1295
ZN;CA;
Assess
Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody AR2 Heteromer
2-1295
ZN;CA;
Assess
Crystal Structure of a Catalytically Active, Non-toxic Endopeptidase Derivative of Clostridium botu… Heteromer
1-872
SO4;ZN;CL;GOL;
Assess
Crystal Structure of BoNT/A-LCHn domain in complex with VNA ciA-D12/11/ciA-B5 and VHH ciA-H7 Heteromer
1-866
Assess
Crystal structure of BoNT/A-LCHn domain in complex with VHH ciA-D12, ciA-B5, and ciA-H7 Heteromer
1-866
Assess
LC/A-JPU-B9-JPU-A11-JPU-G11 Heteromer
2-438
ZN;
Assess
Crystal structure of LC/A-JPU-C10-JPU-D12-JPU-B8-JPU-G3-ciA-F12-ciA-D12 Heteromer
2-431
ZN;
Assess
Crystal structure of BoNT/A receptor binding domain in complex with VHH C2 Heteromer
872-1296
Assess
Receptor binding domain of Botulinum neurotoxin A in complex with human glycosylated SV2C Heteromer
Q496J9;
872-1296
NAG;ACT;PO4;NAG;
Assess
Receptor binding domain of Botulinum neurotoxin A in complex with rat SV2C Heteromer
Q9Z2I6;
872-1296
Assess
Crystal structure of the catalytic domain of Botulinum neurotoxin serotype a with a snap-25 peptide Heteromer
P60880;
1-423
ZN;SO4;
Assess
Crystal structure of the catalytic domain of Botulinum neurotoxin serotype a with a substrate analo… Heteromer
P60880;
1-423
ZN;SO4;
Assess
CRYSTAL STRUCTURE OF THE BOTULINUM NEUROTOXIN A RECEPTOR-BINDING DOMAIN IN COMPLEX WITH THE LUMINAL… Heteromer
Q496J9;
876-1296
CL;NA;
Assess
Crystal structure of BoNT/A-LC-JPU-A5-JPU-C1-JPU-H7-JPU-D12-ciA-F12 Heteromer
1-420
EDO;ZN;
Assess
Crystal structure of NEUROTOXIN BONT/A complexed with Synaptosomal-associated protein 25 Heteromer
P60880;
2-420
ZN;CL;
Assess
Crystal structure of the LC/A1-DARPin18 complex Heteromer
2-420
ZN;
Assess
Crystal Structure of a Llama Antibody complexed with the C. Botulinum Neurotoxin Serotype A Catalyt… Heteromer
3-417
ZN;
Assess
Crystal structure of an engineered botulinum neurotoxin type A- SNARE23 derivative, LC0-A-SNAP25-Hn…homo-2-mer3-865
SO4;
Assess
CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN SEROTYPE Amonomer2-1296
ZN;
Assess
4.3 angstrom crystal structure of an inactive BoNT/A (E224Q/R363A/Y366F)monomer2-1296
ZN;
Assess
Crystal structure of an engineered botulinum neurotoxin type A- SNARE23 derivative, LC-A-SNAP23-Hn-Amonomer3-865
ZN;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134S/C165S double mutantmonomer1-425
ZN;GOL;IMD;EDO;
Assess
Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide boundmonomer1-425
ZN;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134 mutant with MTSEA mod…monomer1-425
ZN;DMS;LMR;GOL;EDO;NA;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134 mutant with MTSEA mod…monomer1-425
ZN;IMD;LMR;DMS;SO4;MPD;LI;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A wild-typemonomer1-425
ZN;EDO;SO4;IMD;CO3;GOL;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134S mutant with covalent…monomer1-425
ZN;SO4;GOL;PEG;PGO;EDO;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134S mutant with covalent…monomer1-425
ZN;PGO;SO4;GOL;
Assess
Structure of the C. botulinum neurotoxin serotype A apo-enzymemonomer1-423
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptid…monomer1-423
ZN;SO4;
Assess
Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibito…monomer1-423
ZN;SO4;
Assess
CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN SEROTYPE A BINDING DOMAIN IN COMPLEX WITH GT1Bmonomer874-1296
BGC;MG;
Assess
Crystal Structure of the Botulinum Neurotoxin Serotype A binding domainmonomer874-1296
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with an acetate ion bo…monomer1-423
ZN;SO4;ACT;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with a Novel Cyclic Pe…monomer1-423
ZN;SO4;
Assess
Structure of the C. botulinum neurotoxin serotype A with Zn2+ cofactor boundmonomer2-423
ZN;
Assess
Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibito…monomer2-423
ZN;SO4;NA;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptid…monomer2-423
ZN;SO4;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptid…monomer2-423
ZN;SO4;
Assess
Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with inhibitory peptid…monomer2-423
ZN;SO4;NA;
Assess
Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibito…monomer2-423
ZN;SO4;NA;
Assess
Crystal structure of the protease domain of Botulinum Neurotoxin Serotype A with a peptide inhibito…monomer2-423
ZN;SO4;NA;EDO;
Assess
Crystal structure of the receptor-binding domain of botulinum neurotoxin A1 (crystal form 1)monomer873-1293
NA;
Assess
The Crystal structure of receptor binding domain of botulinum neurotoxin serotype Amonomer876-1296
Assess
Binding domain of BoNT/A complexed with gangliosidemonomer876-1296
GAL;NGA;
Assess
Structure of the C. botulinum neurotoxin serotype A with Hg boundmonomer2-422
HG;ACT;
Assess
Crystal Structure of HCRA-W1266Amonomer876-1296
GOL;
Assess
Binding domain of BoNT/A complexed with ganglioside variantmonomer876-1296
Assess
Structure of the C. botulinum neurotoxin serotype A with Cu boundmonomer2-422
CU;ACT;
Assess
Clostridium botulinum Serotype A Light Chain inhibited by 4-chlorocinnamic hydroxamatemonomer1-419
ZN;PO4;GB5;
Assess
Botulinum Neurotoxin A Light Chain WT Crystal Form Amonomer2-420
ZN;
Assess
neurotoxin BoNT/A E224Q Y366F mutantmonomer2-420
ZN;
Assess
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chainmonomer1-418
ZN;90J;
Assess
Clostridium botulinum Neurotoxin Serotype A Light Chain, Residues 1-424monomer1-418
ZN;
Assess
Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by L-arginine hydroxamatemonomer1-418
ZN;AHL;
Assess
Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by a Chiral Hydroxamic Acidmonomer1-417
ZN;
Assess
Crystal structure of BoNT/A LC with JTH-NB-7239 peptidemonomer1-417
ZN;NI;
Assess
Clostridium Botulinum Serotype A Light Chain Inhibited By Adamantane Hydroxamatemonomer1-417
ZN;AXM;
Assess
A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformat…monomer2-417
ZN;NI;
Assess
Botulinum Neurotoxin A Light Chain WT Crystal Form Cmonomer2-417
ZN;
Assess
Botulinum Neurotoxin A Light Chain WT Crystal Form Bmonomer2-417
ZN;
Assess
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chainmonomer1-416
ZN;90M;
Assess
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chainmonomer1-416
ZN;90G;
Assess
Botulism Neurooxin Light Chain A app formmonomer3-418
ZN;
Assess
A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformat…monomer3-417
ZN;NI;
Assess
Crystal structure of the receptor-binding domain of botulinum neurotoxin A1 (crystal form 2)monomer886-1295
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3v0a.1.Amonomer0.811-1295
CA;99.69
Assess
2nz9.1.Amonomer0.792-1295
ZN;CA;99.92
Assess